DE60303591D1 - System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen - Google Patents

System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen

Info

Publication number
DE60303591D1
DE60303591D1 DE60303591T DE60303591T DE60303591D1 DE 60303591 D1 DE60303591 D1 DE 60303591D1 DE 60303591 T DE60303591 T DE 60303591T DE 60303591 T DE60303591 T DE 60303591T DE 60303591 D1 DE60303591 D1 DE 60303591D1
Authority
DE
Germany
Prior art keywords
recombinant
production
prokaryontic
host cells
glycosylated protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60303591T
Other languages
English (en)
Other versions
DE60303591T2 (de
Inventor
Markus Aebi
Michael Wacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eidgenoessische Technische Hochschule Zurich ETHZ
Original Assignee
Eidgenoessische Technische Hochschule Zurich ETHZ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eidgenoessische Technische Hochschule Zurich ETHZ filed Critical Eidgenoessische Technische Hochschule Zurich ETHZ
Publication of DE60303591D1 publication Critical patent/DE60303591D1/de
Application granted granted Critical
Publication of DE60303591T2 publication Critical patent/DE60303591T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60303591T 2002-03-07 2003-03-05 System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen Expired - Lifetime DE60303591T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CH394022002 2002-03-07
CH3942002 2002-03-07
US36465502P 2002-03-14 2002-03-14
US364655P 2002-03-14
PCT/CH2003/000153 WO2003074687A1 (en) 2002-03-07 2003-03-05 System and method for the production of recombinant glycosylated proteins in a prokaryotic host

Publications (2)

Publication Number Publication Date
DE60303591D1 true DE60303591D1 (de) 2006-04-20
DE60303591T2 DE60303591T2 (de) 2007-03-01

Family

ID=27789602

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60303591T Expired - Lifetime DE60303591T2 (de) 2002-03-07 2003-03-05 System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen

Country Status (12)

Country Link
US (3) US20050287628A1 (de)
EP (1) EP1481057B1 (de)
KR (1) KR20090110951A (de)
AT (1) ATE317897T1 (de)
AU (1) AU2003205502C1 (de)
CA (1) CA2477794C (de)
DE (1) DE60303591T2 (de)
DK (1) DK1481057T3 (de)
ES (1) ES2258214T3 (de)
IL (3) IL163806A0 (de)
PT (1) PT1481057E (de)
WO (1) WO2003074687A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090110951A (ko) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
EP2853600B1 (de) * 2005-05-11 2018-09-19 ETH Zürich Rekombinante N-glykosylierte Proteine aus prokaryotischen Zellen
AU2011218682B2 (en) * 2005-05-11 2013-11-21 Eth Zurich Recombinant N-glycosylated proteins from procaryotic cells
JP5667880B2 (ja) 2008-01-03 2015-02-12 コーネル リサーチ ファンデーション インコーポレイテッド 原核生物におけるグリコシル化されたタンパク質の発現方法
WO2009104074A2 (en) 2008-02-20 2009-08-27 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HUE038456T2 (hu) 2009-11-19 2018-10-29 Glaxosmithkline Biologicals Sa Bioszintetikus rendszer, amely immunogén poliszaccharidokat termel prokarióta sejtekben
DK2566507T3 (da) 2010-05-06 2018-01-29 Glaxosmithkline Biologicals Sa Biokonjugatvacciner med kapselformige grampositive bakterier
EP2742355B1 (de) 2011-08-12 2018-12-19 The Governors of the University of Alberta Verfahren zur diagnose von bakteriellen infektionen mit bakteriellen glycoproteinen
JP2014526449A (ja) 2011-09-06 2014-10-06 グリコヴァキシン アーゲー 原核細胞において製造されるバイオコンジュゲートワクチン
WO2013067523A1 (en) * 2011-11-04 2013-05-10 Cornell University A prokaryote-based cell-free system for the synthesis of glycoproteins
ES2713166T3 (es) 2012-11-07 2019-05-20 Glaxosmithkline Biologicals Sa Producción de vacuna recombinante en E. coli mediante conjugación enzimática
ES2669420T3 (es) 2013-01-17 2018-05-25 Arsanis Biosciences Gmbh Anticuerpo específico de E.coli MDR
EP2991675B1 (de) * 2013-04-05 2019-07-24 The Governors of the University of Alberta Campylobacter-impfstoff
MX2016011055A (es) 2014-02-24 2017-10-24 Glycovaxyn Ag Nuevo polisacarido y usos del mismo.
ES2939470T3 (es) 2014-04-17 2023-04-24 Glaxosmithkline Biologicals Sa Células hospedadoras modificadas y usos de las mismas
ES2793023T3 (es) 2014-08-08 2020-11-12 Glaxosmithkline Biologicals Sa Células huésped modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
TWI715617B (zh) 2015-08-24 2021-01-11 比利時商葛蘭素史密斯克藍生物品公司 對抗腸道外病原性大腸桿菌之免疫保護之方法及組合物
GB201610599D0 (en) 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
AR109621A1 (es) 2016-10-24 2018-12-26 Janssen Pharmaceuticals Inc Formulaciones de vacunas contra glucoconjugados de expec
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
GB201704117D0 (en) * 2017-03-15 2017-04-26 London School Hygiene & Tropical Medicine Oligosaccharyl Transferase polypeptide
WO2019035916A1 (en) 2017-08-15 2019-02-21 Northwestern University DESIGN OF PROTEIN GLYCOSYLATION SITES BY RAPID EXPRESSION AND CHARACTERIZATION OF N-GLYCOSYLTRANSFERASES
GB201721582D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa S aureus antigens and immunogenic compositions
GB201721576D0 (en) 2017-12-21 2018-02-07 Glaxosmithkline Biologicals Sa Hla antigens and glycoconjugates thereof
US11530432B2 (en) 2018-03-19 2022-12-20 Northwestern University Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates
US11725224B2 (en) 2018-04-16 2023-08-15 Northwestern University Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates
US20210395728A1 (en) * 2018-08-29 2021-12-23 Council Of Scientific & Industrial Research Recombinant microbial system for directed evolution of glycocins and method of preparation thereof
EP3894431A2 (de) 2018-12-12 2021-10-20 GlaxoSmithKline Biologicals SA Modifizierte trägerproteine zur o-verknüpften glykosylierung
CA3126492A1 (en) * 2019-01-11 2020-07-16 Northwestern University Bioconjugate vaccines synthesis in prokaryotic cell lysates
WO2020191082A1 (en) 2019-03-18 2020-09-24 Janssen Pharmaceuticals, Inc. Bioconjugates of e. coli o-antigen polysaccharides, methods of production thereof, and methods of use thereof
AR118389A1 (es) 2019-03-18 2021-09-29 Janssen Pharmaceuticals Inc Métodos de producción de bioconjugados de polisacáridos de e. coli o-antígeno, sus composiciones y métodos de utilización
EP3757217A1 (de) 2019-06-27 2020-12-30 GlaxoSmithKline Biologicals S.A. Verfahren zur proteinaufreinigung
EP3770269A1 (de) 2019-07-23 2021-01-27 GlaxoSmithKline Biologicals S.A. Quantifizierung von biokonjugatglykosylierung
EP3777884A1 (de) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
JP2023530154A (ja) 2020-06-18 2023-07-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 赤痢菌４価（Ｓｈｉｇｅｌｌａ４Ｖ）バイオコンジュゲート
BR112022023234A2 (pt) 2020-06-25 2023-01-03 Glaxosmithkline Biologicals Sa Proteínas de exotoxina a modificada
EP4213870A1 (de) 2020-09-17 2023-07-26 Janssen Pharmaceuticals, Inc. Multivalente impfstoffzusammensetzungen und verwendungen davon
WO2023118033A1 (en) 2021-12-22 2023-06-29 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0170204B1 (de) 1984-08-01 1991-09-25 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Neue genetische Sequenzen, die durch sie codierten Interferon-Peptide vom Typ I und diese sie produzierende Organismen
US5643758A (en) * 1987-03-10 1997-07-01 New England Biolabs, Inc. Production and purification of a protein fused to a binding protein
EP0726318A1 (de) 1993-05-14 1996-08-14 The Upjohn Company Akzeptorpolypeptid für N-Acetylgalaktosaminyltransferase
US6503744B1 (en) 1999-02-01 2003-01-07 National Research Council Of Canada Campylobacter glycosyltransferases for biosynthesis of gangliosides and ganglioside mimics
JP2003524395A (ja) * 1999-03-02 2003-08-19 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 細胞内シアリル化経路の操作
JP2004528001A (ja) * 2000-05-12 2004-09-16 ネオーズ テクノロジーズ， インコーポレイテッド インビトロにおけるフコシル化組換えグリコペプチド
EP1294910B1 (de) 2000-06-30 2008-11-19 VIB vzw Modifikation der proteinglycosylierung in pichia pastoris
KR20090110951A (ko) 2002-03-07 2009-10-23 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서의 재조합 글리코실화 단백질 생산 방법 및 생산계
KR100938026B1 (ko) 2002-03-07 2010-01-21 아이드게노쉬쉐 테흐니쉐 호흐슐레 쥬리히 원핵 숙주에서 재조합 글리코실화 단백질의 생산방법 및생산계
AU2003254665C1 (en) 2002-08-01 2010-08-19 National Research Council Of Canada Campylobacter glycans and glycopeptides
WO2005116063A1 (en) 2004-05-24 2005-12-08 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Live, oral vaccine for protection against shigella dysenteriae serotype 1
EP2853600B1 (de) 2005-05-11 2018-09-19 ETH Zürich Rekombinante N-glykosylierte Proteine aus prokaryotischen Zellen
WO2009104074A2 (en) * 2008-02-20 2009-08-27 Glycovaxyn Ag Bioconjugates made from recombinant n-glycosylated proteins from procaryotic cells
HUE038456T2 (hu) * 2009-11-19 2018-10-29 Glaxosmithkline Biologicals Sa Bioszintetikus rendszer, amely immunogén poliszaccharidokat termel prokarióta sejtekben
DK2566507T3 (da) * 2010-05-06 2018-01-29 Glaxosmithkline Biologicals Sa Biokonjugatvacciner med kapselformige grampositive bakterier

Also Published As

Publication number Publication date
ATE317897T1 (de) 2006-03-15
IL163806A0 (en) 2005-12-18
AU2003205502C1 (en) 2011-08-25
DK1481057T3 (da) 2006-05-15
US20140335127A1 (en) 2014-11-13
US8703471B2 (en) 2014-04-22
IL220322A0 (en) 2012-07-31
EP1481057A1 (de) 2004-12-01
EP1481057B1 (de) 2006-02-15
ES2258214T3 (es) 2006-08-16
KR20090110951A (ko) 2009-10-23
CA2477794A1 (en) 2003-09-12
CA2477794C (en) 2013-08-20
IL163806A (en) 2012-08-30
US20090074798A1 (en) 2009-03-19
AU2003205502A1 (en) 2003-09-16
AU2003205502B2 (en) 2008-01-31
DE60303591T2 (de) 2007-03-01
WO2003074687A1 (en) 2003-09-12
PT1481057E (pt) 2006-05-31
US20050287628A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
DE60303591D1 (de) System und methode zur herstellung von rekombinanten, glykosylierten protein in prokaryontischen wirtszellen
Mukai et al. Highly reproductive Escherichia coli cells with no specific assignment to the UAG codon
Roche et al. Identification of endogenous SsrA-tagged proteins reveals tagging at positions corresponding to stop codons
Doi et al. Elongation factor Tu mutants expand amino acid tolerance of protein biosynthesis system
BRPI0207394B8 (pt) dna codificando uma proteína de fusão proteína codificada por um dna, plasmídeo, micro-organismo hospedeiro, processo para a produção fermentativa de uma proteína de fusão e processo para a produçao de insulina
EP2284189A3 (de) Fibroblasten wachstumsfaktor-ähnliche Polypeptide
EP1179059A4 (de) ISOLIERUNG VON BIOLOGISCHEN MODULATOREN AUS BIBIOTHEKEN MIT BIOLOGISCH VIELFäLTIGEN GENFRAGMENTEN
DK1369486T3 (da) Plasmid-shuttlevektor mellem Escherichia coli og Brevibacillus
ATE545705T1 (de) Neues induzierbares genexpressionssystem auf ecdysonrezeptor/invertebraten-retinoid-x-rezept r-basis
ES2421596T3 (es) Desaminasa inducida por activación (AID)
MX2008011669A (es) Expresion programada geneticamente de proteinas que contienen el aminoacido no natural fenilselenocisteina.
DE60224291D1 (de) System zur antikörperexpression und- synthese
RU2473690C2 (ru) Генетически кодируемые флюоресцентные кумариновые аминокислоты
Delgado-Prudencio et al. The dual α-amidation system in scorpion venom glands
DE3785798D1 (de) Verfahren zur gentechnologischengewinnung von proteinen unter verwendung gramnegativer wirtzellen.
ATE381623T1 (de) Verfahren zur expression von protein mit darin integrierter unnatürlicher aminosäure
ATE454444T1 (de) Verfahren zur herstellung rekombinanter proteine
Wrede et al. Peptide design aided by neural networks: biological activity of artificial signal peptidase I cleavage sites
Sathyamurthy et al. Characterization and expression of proprotein convertases in CHO cells: Efficient proteolytic maturation of human bone morphogenetic protein‐7
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
CN1369014A (zh) 蛋白质生产
Sanggaard et al. TSG-6 transfers proteins between glycosaminoglycans via a Ser28-mediated covalent catalytic mechanism
AU4917300A (en) Method for producing a recombinant protein
Amikura et al. Multiple amino acid-excluded genetic codes for protein engineering using multiple sets of tRNA variants
Campbell et al. Effect of limited proteolysis on the enzymatic phosphorylation of soy protein

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition